Guide
A practical framework for quantifying the cost of poor site selection and calculating the return on data-driven approaches, built for budget conversations and leadership presentations.
Section 1
Before you can calculate ROI, you need to quantify the baseline: what does poor site selection actually cost? The data below, drawn from peer-reviewed research and industry benchmarks, establishes the scope of the problem in terms leadership can act on.
Section 2
A four-step method for translating industry benchmarks into a business case specific to your program and organization.
Start with the specific financial exposure for your compound. Not all programs carry the same risk per month, so generic benchmarks are a starting point, not a conclusion. Build your delay cost from three inputs:
Revenue at risk per month: Estimate peak annual revenue for the compound and divide by 12. A drug expected to generate $1 billion annually represents approximately $83M in monthly peak-revenue exposure for every month the launch is delayed.
Cost per enrolled patient: Across therapeutic areas, patient-level enrollment costs range from $15,000 to over $50,000 when factoring screening, site burden, and dropout. Sites that underenroll inflate this per-patient cost across your entire trial budget.
Site activation cost × underperforming sites: Calculate your average cost to activate a site (including CDA, contract, IRB, and startup overhead). Multiply by the number of sites historically delivering zero or below-projection enrollment. That product is direct, recoverable waste.
Compare your historical site performance against the industry standard. The Tufts CSDD benchmark establishes that 37% of sites underenroll relative to projection. Where do your programs land?
If your underenrollment rate is above industry average, you have clear room for targeted improvement. If you are at or below 37%, the question becomes: what would a 10-point improvement mean in practice?
A practical model: if your typical program activates 60 sites and 22 (37%) historically underenroll, reducing that to 16 sites (27%) frees enrollment capacity equivalent to 6 fully productive sites, without increasing your site count or budget. Depending on your cost-per-site activation, that can represent $1.5M to $4M in recovered investment per trial.
Site startup time is a direct multiplier on your delay cost. Industry-wide, the window from contract execution to first patient screened averages 6 to 9 months. LINEA clients typically see 50% or greater reduction in time to site identification, compressing the earliest phase of that window significantly.
To model this for your program:
Identify your current baseline for time-to-identification in months. Then apply a 50% compression estimate to that phase. Multiply the resulting time savings in months by your monthly delay cost (calculated in Step 1). That product is your projected timeline benefit in dollars.
For a program with a $2M monthly delay cost and a 3-month identification phase, a 50% compression saves approximately 1.5 months, or $3M in direct delay-cost avoidance before any other operational efficiency is counted.
Leadership presentations succeed when they are framed as risk mitigation, not efficiency gains. The distinction matters: efficiency is discretionary; risk management is not. A budget conversation anchored in timeline risk and revenue exposure reaches a different decision-maker than one framed around process improvement.
Structure your case around three scenarios:
| Scenario | Site Underenrollment Rate | Estimated Delay Exposure | Site Activation Waste |
|---|---|---|---|
| Status quo (current approach) | 37% (industry avg.) | Based on your monthly delay cost × estimated slippage months | Activation cost × zero-enrolling sites |
| Data-driven site selection | Target: <20% | Reduced by startup compression × monthly cost | Substantially reduced through pre-selection scoring |
| Difference (recoverable value) | 15–17 percentage points | Program-specific, often $3M–$20M+ | Recoverable per trial |
Section 3
Performance benchmarks across site selection and activation metrics: industry average, top quartile, and LINEA clients.
| Metric | Industry Average | Top Quartile | LINEA Clients |
|---|---|---|---|
| Site identification time | 3–6 months | 6–8 weeks | 2–4 weeks |
| CDA return rate at 7 days | ~30–40% | 50–60% | 50%+ within 7 days |
| Sites that enroll zero patients | 11% | <5% | Minimized through pre-selection scoring |
| Sites that underenroll vs. projection | 37% | <20% | Reduced through RSI matching |
Industry Average and Top Quartile figures derived from Tufts Center for the Study of Drug Development research and publicly available clinical operations benchmarking data. LINEA client figures reflect observed outcomes and are subject to program-specific variation.
Section 4
The strongest business cases for investment in data-driven site selection share a common structural principle: they lead with risk exposure, not feature descriptions. A VP of Clinical Operations or Head of Site Management presenting to a CFO or Chief Medical Officer needs to anchor the conversation in language that resonates at the executive level (timeline risk, revenue delay, and competitive disadvantage) before shifting to operational efficiency.
Frame as risk mitigation, not tooling. Leadership teams that fund site selection improvements are not buying software. They are buying a reduction in the probability of a failed enrollment quarter, a regulatory delay, or a phase III trial that requires a protocol amendment. Every dollar invested in front-end site intelligence is an insurance policy against a much larger back-end cost.
Lead with the cost of the status quo. Before describing what a data-driven approach does, quantify what the current approach costs. Use the framework in Section 2 to attach real numbers to your program, then present the data-driven scenario as the alternative. The delta between the two scenarios is the investment's value, stated in terms leadership already owns.
Use timeline compression as competitive advantage. In competitive therapeutic areas, the first drug to complete enrollment and submit an NDA holds a structural market-entry advantage. Site selection speed is not just an operational efficiency: it is a competitive variable. Framing startup compression in those terms elevates the conversation from process to strategy.
Anchor cost avoidance, not just cost reduction. Budget-holders respond more readily to costs that will not be incurred than to costs that will decrease. Structure your business case around cost avoidance: activation dollars not spent on zero-enrolling sites, delay costs not realized due to faster identification, and amendment costs avoided through better site-protocol fit.
See It in Practice
Request a demo to see how LINEA's RSI scoring and site intelligence platform applies this framework to your specific indication, geography, and site network.
Sources: Tufts Center for the Study of Drug Development; industry benchmarks compiled from publicly available clinical trial performance data. Monthly Phase III delay cost range reflects therapy area and addressable market variation; oncology programs represent the high end of the stated range. LINEA client benchmarks reflect observed program outcomes and may vary.